Orion Market Research Pvt. Ltd. info@omrglobal.com +91 780-304-0404
Help Center
Careers
Contact

Meperidine Market

Meperidine Market Size, Share & Trends Analysis Report, By Product Type (Injectable Meperidine, Oral Meperidine (Tablets / Syrup)), By End-User (Hospitals, Ambulatory Surgical Centers (ASCs), Clinics, Homecare Settings), By Manufacturing Type (Branded Meperidine, Generic Meperidine), By Packaging Type (Ampoules / Vials (Injectables), Blister Packs (Tablets), Bottles (Liquid formulations)), Forecast Period (2026-2035)

Published: May 2026 | Report Code: OMR2029592 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Meperidine market size was valued at $1.30 billion in 2025 and is projected to reach $2.04 billion by 2035, growing at a CAGR of 4.6% between 2026 and 2035. The market consists of opioid analgesics used in controlled clinical environments for short-term pain management, particularly in surgical and emergency settings. Meperidine plays an important role in perioperative care due to its rapid onset and effectiveness in acute pain scenarios. A key driver supporting market growth is the increasing number of surgical procedures globally. According to the World Health Organization, over 313 million surgical procedures are performed annually, highlighting strong demand for perioperative pain management drugs. Additionally, the U.S. Food and Drug Administration emphasizes continued use of opioid analgesics in regulated clinical environments for effective short-term pain relief. Increasing hospital infrastructure and expansion of healthcare services are further supporting demand for injectable analgesics across global markets.

Market Dynamics

Rising Surgical Procedures Driving Market Growth

The increasing volume of surgical procedures and hospital admissions is a major factor driving the meperidine market. The rising burden of chronic diseases and trauma cases is increasing the demand for effective pain management solutions. According to the World Health Organization, surgical interventions continue to represent a significant portion of global healthcare demand, supporting the use of analgesics in postoperative care. Additionally, the OECD highlights increasing healthcare expenditure across developed economies, improving access to advanced medical treatments.

Pharmaceutical manufacturers are focusing on expanding injectable production capacity and strengthening supply chains between 2023 and 2026 to meet hospital demand. Companies are also aligning with regulatory frameworks to ensure safe opioid usage, which supports continued adoption in clinical environments.

Raw Material Cost and Regulatory Constraints Limiting Market Growth

Despite steady demand, the meperidine market faces challenges due to strict opioid regulations and safety concerns. Meperidine is associated with risks such as dependency and adverse effects, leading to cautious prescribing practices. According to the U.S. Food and Drug Administration, opioid medications require strict monitoring due to potential misuse, impacting prescribing trends globally.

Additionally, regulatory restrictions and increasing preference for alternative therapies are limiting market growth. Supply chain complexities and compliance requirements for controlled substances also increase operational costs. Companies are focusing on improving safety standards and regulatory compliance to maintain market stability.

Market Segmentation

  • Based on the product type, the market is segmented into injectable meperidine and oral meperidine (tablets / syrup).
  • Based on the end-user, the market is segmented into hospitals, ambulatory surgical centers (ASCs), clinics, and homecare settings.
  • Based on the manufacturing type, the market is segmented into branded meperidine and generic meperidine.
  • Based on the packaging type, the market is segmented into ampoules / vials (injectables), blister packs (tablets), and bottles (liquid formulations).

Injectable Meperidine Segment Leads the Market

The injectable meperidine segment holds a dominant position in the meperidine market due to its rapid onset of action and widespread use in hospital and surgical environments. Injectable formulations are preferred in acute care settings as they provide immediate pain relief, which is critical during emergency procedures, trauma cases, and postoperative recovery. These formulations are commonly administered through intravenous (IV) or intramuscular (IM) routes, enabling precise dosage control and faster therapeutic response compared to oral alternatives. The growing number of surgical procedures globally is a key factor driving segment demand. According to the World Health Organization, over 313 million surgical procedures are performed annually, significantly increasing the need for effective perioperative pain management solutions. Injectable meperidine is frequently used in controlled hospital settings where rapid analgesic intervention is required, particularly in short-duration procedures and recovery phases.

Ambulatory Surgical Centers Segment to Record Strong Growth

The ambulatory surgical centers (ASCs) segment is expected to grow rapidly due to the increasing shift toward outpatient procedures and cost-efficient healthcare services. ASCs enable faster patient turnover and reduced hospital stays, driving demand for short-acting analgesics like meperidine. Additionally, rising investments in outpatient healthcare infrastructure and minimally invasive surgeries are further supporting the expansion of this segment.

Regional Outlook

The global Meperidine market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States dominates the market due to advanced healthcare systems and high surgical procedure volumes. According to the U.S. Food and Drug Administration, strict regulatory frameworks ensure controlled usage of opioid medications.

China to Record Strong Growth

China is expected to witness strong growth due to expanding healthcare infrastructure and increasing pharmaceutical production. According to the International Trade Centre, pharmaceutical trade activities are increasing in the region.

Competitive Landscape

The meperidine market is moderately competitive, characterized by the presence of global pharmaceutical manufacturers and generic drug producers. Leading companies such as Pfizer Inc., Hikma Pharmaceuticals, Mallinckrodt Pharmaceuticals, Sanofi S.A., and Teva Pharmaceutical Industries are focusing on strengthening product portfolios and improving manufacturing capabilities.

Recent Developments

  • In March 2026, Pfizer announced positive Phase 3 TALAPRO-3 study results, where TALZENNA® (talazoparib) in combination with XTANDI® demonstrated significant improvement in radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer. The results support expanded therapeutic potential and strengthen Pfizer’s oncology pipeline with targeted combination therapies.
  • In March 2026, Hikma Pharmaceuticals launched an authorised generic version of Nucynta® ER (tapentadol extended-release) in the U.S., marking the first generic availability of the product following its earlier immediate-release launch. This expansion strengthens Hikma’s pain management portfolio and enhances patient access to cost-effective opioid analgesics in the U.S. market.

The Report Covers

  • Market value data analysis of 2025 and forecast to 2035.
  • Annualised market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global Meperidine market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.
  1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
    • Global Meperidine Market Sales Analysis – Product Type | End-User | Manufacturing Type | Packaging Type ($ Million)
    • Meperidine Market Sales Performance of Top Countries

1.1 Research Methodology

  • Primary Research Approach
    • Secondary Research Approach

1.2 Market Snapshot

  1. Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

2.2.1 Key Meperidine Market Trends
2.2.2 Market Recommendations

2.3 Porter's Five Forces Analysis for the Meperidine Market

2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes

  1. Market Determinants

3.1 Market Drivers

3.1.1 Drivers For Global Meperidine Market: Impact Analysis

3.2 Market Pain Points and Challenges

3.2.1 Restraints For Global Meperidine Market: Impact Analysis

3.3 Market Opportunities

3.3.1 Opportunities For Global Meperidine Market: Impact Analysis

  1. Competitive Landscape

4.1 Competitive Dashboard – Meperidine Market Revenue and Share by Manufacturers

  • Meperidine Product Comparison Analysis
    • Top Market Player Ranking Matrix

4.2 Key Company Analysis

4.2.1 Pfizer Inc.

4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy

4.2.2 Hikma Pharmaceuticals

4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy

4.2.3 Mallinckrodt Pharmaceuticals

4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy

4.2.4 Sanofi S.A.

4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy

4.2.5 Teva Pharmaceutical Industries

4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy

4.3 Top Winning Strategies by Market Players

4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration

  1. Global Meperidine Market Sales Analysis by Product Type ($ Million)

5.1 Injectable Meperidine
5.2 Oral Meperidine (Tablets / Syrup)

  1. Global Meperidine Market Sales Analysis by End-User ($ Million)

6.1 Hospitals
6.2 Ambulatory Surgical Centres (ASCs)
6.3 Clinics
6.4 Homecare Settings

  1. Global Meperidine Market Sales Analysis by Manufacturing Type ($ Million)

7.1 Branded Meperidine
7.2 Generic Meperidine

  1. Global Meperidine Market Sales Analysis by Packaging Type ($ Million)

8.1 Ampoules / Vials (Injectables)
8.2 Blister Packs (Tablets)
8.3 Bottles (Liquid formulations)

  1. Regional Analysis

9.1 North American Meperidine Market Sales Analysis – Product Type | End-User | Manufacturing Type | Packaging Type ($ Million)

9.1.1 United States
9.1.2 Canada

9.2 European Meperidine Market Sales Analysis – Product Type | End-User | Manufacturing Type | Packaging Type ($ Million)

9.2.1 UK
9.2.2 Germany
9.2.3 Italy
9.2.4 Spain
9.2.5 France
9.2.6 Russia
9.2.7 Rest of Europe

9.3 Asia-Pacific Meperidine Market Sales Analysis – Product Type | End-User | Manufacturing Type | Packaging Type ($ Million)

9.3.1 China
9.3.2 Japan
9.3.3 South Korea
9.3.4 India
9.3.5 Australia & New Zealand
9.3.6 ASEAN Countries
9.3.7 Rest of Asia-Pacific

9.4 Rest of the World Meperidine Market Sales Analysis – Product Type | End-User | Manufacturing Type | Packaging Type ($ Million)

9.4.1 Latin America
9.4.2 Middle East and Africa

  1. Company Profiles

10.1 Bio-Rad Laboratories
10.1.1 Quick Facts
10.1.2 Company Overview
10.1.3 Product Portfolio
10.1.4 Business Strategies

10.2 Biosano SA
10.2.1 Quick Facts
10.2.2 Company Overview
10.2.3 Product Portfolio
10.2.4 Business Strategies

10.3 Epic Pharma LLC
10.3.1 Quick Facts
10.3.2 Company Overview
10.3.3 Product Portfolio
10.3.4 Business Strategies

10.4 Genus Lifesciences Inc.
10.4.1 Quick Facts
10.4.2 Company Overview
10.4.3 Product Portfolio
10.4.4 Business Strategies

10.5 Hameln Pharma
10.5.1 Quick Facts
10.5.2 Company Overview
10.5.3 Product Portfolio
10.5.4 Business Strategies

10.6 ICU Medical Inc.
10.6.1 Quick Facts
10.6.2 Company Overview
10.6.3 Product Portfolio
10.6.4 Business Strategies

10.7 Johnson Matthey
10.7.1 Quick Facts
10.7.2 Company Overview
10.7.3 Product Portfolio
10.7.4 Business Strategies

10.8 Lupin Pharmaceuticals, Inc.
10.8.1 Quick Facts
10.8.2 Company Overview
10.8.3 Product Portfolio
10.8.4 Business Strategies

10.9 Martindale Pharma
10.9.1 Quick Facts
10.9.2 Company Overview
10.9.3 Product Portfolio
10.9.4 Business Strategies

10.10 Micro Labs Ltd.
10.10.1 Quick Facts
10.10.2 Company Overview
10.10.3 Product Portfolio
10.10.4 Business Strategies

10.11 Northeast Pharmaceutical Group
10.11.1 Quick Facts
10.11.2 Company Overview
10.11.3 Product Portfolio
10.11.4 Business Strategies

10.12 Quagen Pharmaceuticals
10.12.1 Quick Facts
10.12.2 Company Overview
10.12.3 Product Portfolio
10.12.4 Business Strategies

10.13 Rusan Pharma Ltd.
10.13.1 Quick Facts
10.13.2 Company Overview
10.13.3 Product Portfolio
10.13.4 Business Strategies

10.14 Sandoz Group AG
10.14.1 Quick Facts
10.14.2 Company Overview
10.14.3 Product Portfolio
10.14.4 Business Strategies

10.15 Siegfried Holding AG
10.15.1 Quick Facts
10.15.2 Company Overview
10.15.3 Product Portfolio
10.15.4 Business Strategies

10.16 Sterling Pharma Solutions
10.16.1 Quick Facts
10.16.2 Company Overview
10.16.3 Product Portfolio
10.16.4 Business Strategies

10.17 Strides Pharma Science Ltd.
10.17.1 Quick Facts
10.17.2 Company Overview
10.17.3 Product Portfolio
10.17.4 Business Strategies

10.18 Sun Pharmaceutical Industries
10.18.1 Quick Facts
10.18.2 Company Overview
10.18.3 Product Portfolio
10.18.4 Business Strategies

10.19 UQUIFA S.A.U.
10.19.1 Quick Facts
10.19.2 Company Overview
10.19.3 Product Portfolio
10.19.4 Business Strategies

10.20 Verve Health Care Ltd.
10.20.1 Quick Facts
10.20.2 Company Overview
10.20.3 Product Portfolio
10.20.4 Business Strategies

1. Global Meperidine Market Research and Analysis by Product Type, 2025–2035 ($ Million) 

2. Global Injectable Meperidine Market Research and Analysis by Region, 2025–2035 ($ Million) 

3. Global Oral Meperidine Market Research and Analysis by Region, 2025–2035 ($ Million) 

4. Global Meperidine Market Research and Analysis by End-User, 2025–2035 ($ Million) 

5. Global Meperidine for Hospitals Research and Analysis by Region, 2025–2035 ($ Million) 

6. Global Meperidine for Ambulatory Surgical Centres (ASCs) Research and Analysis by Region, 2025–2035 ($ Million) 

7. Global Meperidine for Clinics Research and Analysis by Region, 2025–2035 ($ Million) 

8. Global Meperidine for Homecare Settings Research and Analysis by Region, 2025–2035 ($ Million) 

9. Global Meperidine Market Research and Analysis by Manufacturing Type, 2025–2035 ($ Million) 

10. Global Branded Meperidine Market Research and Analysis by Region, 2025–2035 ($ Million) 

11. Global Generic Meperidine Market Research and Analysis by Region, 2025–2035 ($ Million) 

12. Global Meperidine Market Research and Analysis by Packaging Type, 2025–2035 ($ Million) 

13. Global Ampoules / Vials Meperidine Market Research and Analysis by Region, 2025–2035 ($ Million) 

14. Global Blister Packs Meperidine Market Research and Analysis by Region, 2025–2035 ($ Million) 

15. Global Bottles Meperidine Market Research and Analysis by Region, 2025–2035 ($ Million) 

16. Global Meperidine Market Research and Analysis by Region, 2025–2035 ($ Million) 

17. North America Meperidine Market Research and Analysis by Country, 2025–2035 ($ Million) 

18. North America Meperidine Market Research and Analysis by Product Type, 2025–2035 ($ Million) 

19. North America Meperidine Market Research and Analysis by End-User, 2025–2035 ($ Million) 

20. North America Meperidine Market Research and Analysis by Manufacturing Type, 2025–2035 ($ Million) 

21. North America Meperidine Market Research and Analysis by Packaging Type, 2025–2035 ($ Million) 

22. Europe Meperidine Market Research and Analysis by Country, 2025–2035 ($ Million) 

23. Europe Meperidine Market Research and Analysis by Product Type, 2025–2035 ($ Million) 

24. Europe Meperidine Market Research and Analysis by End-User, 2025–2035 ($ Million) 

25. Europe Meperidine Market Research and Analysis by Manufacturing Type, 2025–2035 ($ Million) 

26. Europe Meperidine Market Research and Analysis by Packaging Type, 2025–2035 ($ Million) 

27. Asia-Pacific Meperidine Market Research and Analysis by Country, 2025–2035 ($ Million) 

28. Asia-Pacific Meperidine Market Research and Analysis by Product Type, 2025–2035 ($ Million) 

29. Asia-Pacific Meperidine Market Research and Analysis by End-User, 2025–2035 ($ Million) 

30. Asia-Pacific Meperidine Market Research and Analysis by Manufacturing Type, 2025–2035 ($ Million) 

31. Asia-Pacific Meperidine Market Research and Analysis by Packaging Type, 2025–2035 ($ Million) 

32. Rest of the World Meperidine Market Research and Analysis by Region, 2025–2035 ($ Million) 

33. Rest of the World Meperidine Market Research and Analysis by Product Type, 2025–2035 ($ Million) 

34. Rest of the World Meperidine Market Research and Analysis by End-User, 2025–2035 ($ Million) 

35. Rest of the World Meperidine Market Research and Analysis by Manufacturing Type, 2025–2035 ($ Million) 

36. Rest of the World Meperidine Market Research and Analysis by Packaging Type, 2025–2035 ($ Million) 

1. Global Meperidine Market Share by Product Type, 2025 Vs 2035 (%) 

2. Global Injectable Meperidine Market Share by Region, 2025 Vs 2035 (%) 

3. Global Oral Meperidine Market Share by Region, 2025 Vs 2035 (%) 

4. Global Meperidine Market Share by End-User, 2025 Vs 2035 (%) 

5. Global Meperidine for Hospitals Share by Region, 2025 Vs 2035 (%) 

6. Global Meperidine for Ambulatory Surgical Centres (ASCs) Share by Region, 2025 Vs 2035 (%) 

7. Global Meperidine for Clinics Share by Region, 2025 Vs 2035 (%) 

8. Global Meperidine for Homecare Settings Share by Region, 2025 Vs 2035 (%) 

9. Global Meperidine Market Share by Manufacturing Type, 2025 Vs 2035 (%) 

10. Global Branded Meperidine Market Share by Region, 2025 Vs 2035 (%) 

11. Global Generic Meperidine Market Share by Region, 2025 Vs 2035 (%) 

12. Global Meperidine Market Share by Packaging Type, 2025 Vs 2035 (%) 

13. Global Ampoules / Vials Meperidine Market Share by Region, 2025 Vs 2035 (%) 

14. Global Blister Packs Meperidine Market Share by Region, 2025 Vs 2035 (%) 

15. Global Bottles Meperidine Market Share by Region, 2025 Vs 2035 (%) 

16. Global Meperidine Market Share by Region, 2025 Vs 2035 (%) 

17. US Meperidine Market Size, 2025–2035 ($ Million) 

18. Canada Meperidine Market Size, 2025–2035 ($ Million) 

19. UK Meperidine Market Size, 2025–2035 ($ Million) 

20. France Meperidine Market Size, 2025–2035 ($ Million) 

21. Germany Meperidine Market Size, 2025–2035 ($ Million) 

22. Italy Meperidine Market Size, 2025–2035 ($ Million) 

23. Spain Meperidine Market Size, 2025–2035 ($ Million) 

24. Russia Meperidine Market Size, 2025–2035 ($ Million) 

25. India Meperidine Market Size, 2025–2035 ($ Million) 

26. China Meperidine Market Size, 2025–2035 ($ Million) 

27. Japan Meperidine Market Size, 2025–2035 ($ Million) 

28. South Korea Meperidine Market Size, 2025–2035 ($ Million) 

29. Australia & New Zealand Meperidine Market Size, 2025–2035 ($ Million) 

30. ASEAN Meperidine Market Size, 2025–2035 ($ Million) 

31. Rest of Asia-Pacific Meperidine Market Size, 2025–2035 ($ Million) 

32. Latin America Meperidine Market Size, 2025–2035 ($ Million) 

33. Middle East & Africa Meperidine Market Size, 2025–2035 ($ Million)

Choose License Type
    On Discount
Enterprise Custom
  • Printable version
  • No restriction to number of users within the company
CONTACT SALES

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports

FAQS

The size of the Meperidine Market in 2025 is estimated to be around $1.30 billion.
United States holds the largest share in the Meperidine Market.
Leading players in the Meperidine Market Includes Pfizer Inc., Hikma Pharmaceuticals, Mallinckrodt Pharmaceuticals, Sanofi S.A., and Teva Pharmaceutical Industries., among others.
The Meperidine Market is expected to grow at a CAGR of 4.6% from 2026 to 2035.
Increasing demand for pain management therapies, rising number of surgical procedures, and growing prevalence of chronic pain conditions are driving the Meperidine Market growth.